Anthracycline in colorectal carcinoma: an in vitro short-term assay to predict drug sensitivity. Preliminary results.
The chemosensitivity of 26 non-pretreated colorectal carcinomas (primary tumors and/or colorectal metastases) was studied by an in vitro antimetabolic assay, which evaluates the interference of drugs on the incorporation of 3H-thymidine and 3H-uridine in short-term cultures of human tumors. Our results correlate with the response rate obtained in clinical studies with monochemotherapy and justify the possibility of a future prospective study using individually tailored chemotherapy regimens. Doxorubicin-analogues, with an overall in vitro efficacy in 16.0% and 14.3% for 4-epidoxorubicin (epi-DX) and 4-deoxydoxorubicin (deo-DX), respectively, seem to deserve a modest role in the treatment of colorectal cancer, provided that a careful selection of patients is performed. Variability in anthracycline activity is indeed evident, also in our study, in relation to the different neoplastic picture of the various patients.
Seminara
P
P
Franchi
F
F
Mulieri
M
M
D'Amelio
R
R
Codacci Pisanelli
G
G
Aronne
T
T
Manfredi
D
D
D003110:Colonic Neoplasms / Q000473:pathology*; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D015251:Epirubicin; D006801:Humans; D066298:In Vitro Techniques; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary*; D012334:RNA, Neoplasm / Q000032:analysis; D012004:Rectal Neoplasms / Q000473:pathology*
D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D015251:Epirubicin; D004317:Doxorubicin; C030851:esorubicin